Targeted therapies: how personal should we go? (original) (raw)

• Tejpar, S. et al. Mutant KRAS and BRAF gene expression profiles in colorectal cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60–00 trial [abstract]. J. Clin. Oncol. 28 (Suppl.), a3511 (2010).
  Google Scholar
• Wirapati, P. et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10, R65 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Blows, F. M. et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 7, e1000279 (2010).
  Article PubMed PubMed Central Google Scholar
• Cetin, K., Ettinger, D. S., Hei, Y. J. & O'Malley, C. D. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin. Epidemiol. 3, 139–148 (2011).
  Article PubMed PubMed Central Google Scholar
• Roth, J. A. & Carlson, J. J. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin. Lung Cancer 12, 393–401 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
  Article PubMed PubMed Central Google Scholar
• Welcome Trust Sanger Institute. Scientific Resources [online], (2011).
• Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108–1113 (2007).
  Article CAS PubMed Google Scholar
• Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159–170 (1996).
  Article CAS PubMed Google Scholar
• Torkamani, A., Verkhivker, G. & Schork, N. J. Cancer driver mutations in protein kinase genes. Cancer Lett. 281, 117–127 (2009).
  Article CAS PubMed Google Scholar
• EMA. European Medicines Agency [online], (2011).
• FDA. U.S. Food and Drug Administration [online], (2011).
• Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561–566 (1996).
  Article CAS PubMed Google Scholar
• Hirota, S. et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J. Pathol. 193, 505–510 (2001).
  Article CAS PubMed Google Scholar
• Heinrich, M. C. et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299, 708–710 (2003).
  Article CAS PubMed Google Scholar
• Antonescu, C. R. et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin. Cancer Res. 9, 3329–3337 (2003).
  CAS PubMed Google Scholar
• Blanke, C. D. et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26, 620–625 (2008).
  Article CAS PubMed Google Scholar
• Lasota, J. et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am. J. Pathol. 157, 1091–1095 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Heinrich, M. C. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342–4349 (2003).
  Article CAS PubMed Google Scholar
• Debiec-Rychter, M. et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 42, 1093–1103 (2006).
  Article CAS PubMed Google Scholar
• Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).
  Article CAS PubMed Google Scholar
• Gianni, L. et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12, 236–244 (2011).
  Article CAS PubMed Google Scholar
• Esteva, F. J. et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 1800–1808 (2002).
  Article CAS PubMed Google Scholar
• Morrow, P. K. et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J. Clin. Oncol. 29, 3126–3132 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Nahta, R., Hung, M. C. & Esteva, F. J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 64, 2343–2346 (2004).
  Article CAS PubMed Google Scholar
• Seidman, A. D. et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J. Clin. Oncol. 26, 1642–1649 (2008).
  Article CAS PubMed Google Scholar
• Pritchard, K. I. et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 354, 2103–2111 (2006).
  Article CAS PubMed Google Scholar
• Wolff, A. C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118–145 (2007).
  Article CAS PubMed Google Scholar
• Kaufman, P. A. et al. CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2– metastatic breast cancer (MBC) [abstract]. J. Clin. Oncol. 25 (Suppl.), a1009 (2007).
  Google Scholar
• Perez, E. A. et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J. Clin. Oncol. 28, 4307–4315 (2010).
  Article PubMed PubMed Central Google Scholar
• Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
  Article CAS PubMed Google Scholar
• Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719–726 (2002).
  Article CAS PubMed Google Scholar
• Nahta, R., Yu, D., Hung, M. C., Hortobagyi, G. N. & Esteva, F. J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 3, 269–280 (2006).
  Article CAS PubMed Google Scholar
• Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997).
  Article CAS PubMed Google Scholar
• Nagata, Y. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117–127 (2004).
  Article CAS PubMed Google Scholar
• Saal, L. H. et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65, 2554–2559 (2005).
  Article CAS PubMed Google Scholar
• Berns, K. et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395–402 (2007).
  Article CAS PubMed Google Scholar
• Razis, E. et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res. Treat. 128, 447–456 (2011).
  Article CAS PubMed Google Scholar
• Esteva, F. J. et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am. J. Pathol. 177, 1647–1656 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
  Article CAS PubMed Google Scholar
• Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
  Article CAS PubMed Google Scholar
• Morinaga, R. et al. Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer. Cancer Sci. 99, 2455–2460 (2008).
  Article CAS PubMed Google Scholar
• Cappuzzo, F. et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl Cancer Inst. 97, 643–655 (2005).
  Article CAS PubMed Google Scholar
• Marks, J. L. et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J. Thorac. Oncol. 3, 111–116 (2008).
  Article PubMed Google Scholar
• Cohen, M. H. et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 10, 1212–1218 (2004).
  Article CAS PubMed Google Scholar
• Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163–1167 (2004).
  Article CAS PubMed Google Scholar
• Pao, W. & Girard, N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12, 175–180 (2011).
  Article CAS PubMed Google Scholar
• Gazdar, A. F. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 (Suppl. 1), S24–S31 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Greulich, H. et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2, e313 (2005).
  Article PubMed PubMed Central CAS Google Scholar
• Ichihara, S. et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int. J. Cancer 120, 1239–1247 (2007).
  Article CAS PubMed Google Scholar
• Carey, K. D. et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66, 8163–8171 (2006).
  Article CAS PubMed Google Scholar
• Mulloy, R. et al. Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 67, 2325–2330 (2007).
  Article CAS PubMed Google Scholar
• Jackman, D. M. et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin. Cancer Res. 12, 3908–3914 (2006).
  Article CAS PubMed Google Scholar
• Riely, G. J. et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12, 839–844 (2006).
  Article CAS PubMed Google Scholar
• Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958–967 (2009).
  Article CAS PubMed Google Scholar
• Won, Y. W. et al. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. J. Clin. Pathol. 64, 947–952 (2011).
  Article CAS PubMed Google Scholar
• Yasuda, H., Kobayashi, S. & Costa, D. B. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(11)70129-2.
• Shigematsu, H. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97, 339–346 (2005).
  Article CAS PubMed Google Scholar
• Hsieh, M. H. et al. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer 53, 311–322 (2006).
  Article PubMed Google Scholar
• Chou, T. Y. et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin. Cancer Res. 11, 3750–3757 (2005).
  Article CAS PubMed Google Scholar
• Wu, J. Y. et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin. Cancer Res. 14, 4877–4882 (2008).
  Article CAS PubMed Google Scholar
• Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
  Article CAS PubMed Google Scholar
• Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041–3046 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Joseph, E. W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA 107, 14903–14908 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kopetz, S. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors [abstract]. J. Clin.. Oncol. 28 (Suppl.), a3534 (2010).
  Article Google Scholar
• Xing, F. et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene http://dx.doi.org/10.1038/onc.2011.250.
• Benvenuti, S. et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67, 2643–2648 (2007).
  Article CAS PubMed Google Scholar
• Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008).
  Article CAS PubMed Google Scholar
• Lievre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992–3995 (2006).
  Article CAS PubMed Google Scholar
• Loupakis, F. et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br. J. Cancer 101, 715–721 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Linardou, H. et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9, 962–972 (2008).
  Article CAS PubMed Google Scholar
• Di Nicolantonio, F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705–5712 (2008).
  Article CAS PubMed Google Scholar
• De Roock, W. et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11, 753–762 (2010).
  Article CAS PubMed Google Scholar
• Gupta, S. et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129, 957–968 (2007).
  Article CAS PubMed Google Scholar
• Cantley, L. C. & Neel, B. G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad. Sci. USA 96, 4240–4245 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Sartore-Bianchi, A. et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69, 1851–1857 (2009).
  Article CAS PubMed Google Scholar
• Prenen, H. et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin. Cancer Res. 15, 3184–3188 (2009).
  Article CAS PubMed Google Scholar
• Perrone, F. et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann. Oncol. 20, 84–90 (2009).
  Article CAS PubMed Google Scholar
• Zhao, L. & Vogt, P. K. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl Acad. Sci. USA 105, 2652–2657 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Frattini, M. et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 97, 1139–1145 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Loupakis, F. et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J. Clin. Oncol. 27, 2622–2629 (2009).
  Article CAS PubMed Google Scholar
• Moroni, M. et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6, 279–286 (2005).
  Article CAS PubMed Google Scholar
• Tejpar, S. et al. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab [abstract]. J. Clin. Oncol. 29 (Suppl.), a3511 (2011).
  Article Google Scholar
• De Roock, W. et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304, 1812–1820 (2010).
  Article CAS PubMed Google Scholar
• Janakiraman, M. et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 70, 5901–5911 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Edkins, S. et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol. Ther. 5, 928–932 (2006).
  Article CAS PubMed Google Scholar
• Feig, L. A. & Cooper, G. M. Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins. Mol. Cell Biol. 8, 2472–2478 (1988).
  Article CAS PubMed PubMed Central Google Scholar
• Bos, J. L. Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689 (1989).
  CAS PubMed Google Scholar
• Andreyev, H. J., Norman, A. R., Cunningham, D., Oates, J. R. & Clarke, P. A. Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J. Natl Cancer Inst. 90, 675–684 (1998).
  Article CAS PubMed Google Scholar
• Almoguera, C. et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549–554 (1988).
  Article CAS PubMed Google Scholar
• Urban, T. et al. Detection of codon 12 K-ras mutations in non-neoplastic mucosa from bronchial carina in patients with lung adenocarcinomas. Br. J. Cancer 82, 412–417 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Bennecke, M. et al. Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 18, 135–146 (2011).
  Article CAS Google Scholar
• Stemke-Hale, K. et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 68, 6084–6091 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Vasudevan, K. M. et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16, 21–32 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Loi, S. et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc. Natl Acad. Sci. USA 107, 10208–10213 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Chmielecki, J. et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med. 3, 90ra59 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Fodde, R., Smits, R. & Clevers, H. APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer 1, 55–67 (2001).
  Article CAS PubMed Google Scholar
• Fearnhead, N. S., Britton, M. P. & Bodmer, W. F. The ABC of APC. Hum. Mol. Genet. 10, 721–733 (2001).
  Article CAS PubMed Google Scholar